Targeting STAT3 and STAT5 in Cancer

• Otros Autores: Moriggl, Richard (Editor), Gunning, Patrick (Editor), Keserü, György Miklós (Editor)
• Formato: Electrónico Capítulo de libro
• Lenguaje: inglés
• Publicado: Basel, Switzerland MDPI - Multidisciplinary Digital Publishing Institute 2020
• Materias: Research & information: general; Biology, life sciences; multiple myeloma; STAT3; S3I-1757; nanoparticle; CD38; siRNA/RNAi; polyethylenimine; PEI; lipopolyplex; siRNA delivery; glioma; glioblastoma; STAT5; AKT; ERK1/2; prolactin; androgens; prostate cancer; knockout; escape mechanisms; stem/progenitor cells; cell hierarchy; cancer; CD4+ T cells; CD8+ T cells; myeloid cells; immune check point; hepatitis C virus (HCV); cirrhosis; hepatocellular carcinoma (HCC); endoplasmic reticulum (ER) stress; oxidative stress (OS); unfolded protein response (UPR); microRNA-122 (miR-122); nuclear factor erythroid 2-related factor 2 (NRF2); signal transducer and activator of transcription 3 (STAT3); hepatocyte nuclear factor 4 alpha (HNF4A); solid cancers; cell cycle; apoptosis; inflammation; mitochondria; stemness; tumor suppression; melanoma; autoimmune disease; immunotherapy; tumor-immune cell interactions; breast cancer; PD-L1; M2 macrophages; NK cells; STAT3 inhibitor XIII; hedging; transaction costs; dynamic programming; risk management; post-decision state variable; cancer progression; cancer-stem cell; cytokine; therapy resistance; metastasis; immunosuppression; tumor microenvironment; proliferation; tyrosine kinase 2; JAK family of protein tyrosine kinases; signal transducer and activator of transcription; cytokine receptor signaling; gain-of-function mutation; tumorigenesis; ADAM17; interleukin-6; trans-signaling; epidermal growth factor receptor (EGF-R); shedding; metalloprotease; tumor necrosis factor alpha (TNFα); inflammation associated cancer; colon cancer; lung cancer; SH2 domain; mutations; autosomal-dominant hyper IgE syndrome; inflammatory hepatocellular adenomas; T-cell large granular lymphocytic leukemia; T-cell prolymphocytic leukemia; growth hormone insensitivity syndrome; nuclear pore complex; nuclear transport receptors; nucleocytoplasmic shuttling; targeting; tumor-associated macrophages; adoptive T cell therapy; immune suppression; STAT transcription factors; JAK; STAT; T-PLL; T-cell leukemia; meta-analysis; STAT5B signaling; small-molecule inhibitors; cancer models; companion animals; comparative oncology; pharmacological inhibitor; STAT5 signaling; chemotherapy resistance; myeloid leukemia; heat shock proteins; chaperones; stabilization; targeted therapy; ovarian cancer; hematopoietic cancers; therapeutic targeting; pharmacological inhibitors; mTOR; Bone Marrow Failure Syndromes; lymphocytes; lymphoma; T-cells; RHOA; NGS; MPN; JAK2 V617F; neoplastic stem cells; n/a
• Acceso en línea: DOAB: download the publication; DOAB: description of the publication

Every minute, 34 new patients are diagnosed with cancer globally. Although over the past 50 years treatments have improved and survival rates have increased dramatically for several types of cancers, many remain incurable. Several aggressive types of blood and solid cancers form when mutations occur...